A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
Sponsor: |
Vor Biopharma |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAU4826 |
U.S. Govt. ID: |
NCT04849910 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
You are being asked to take part in this study because you have acute myeloid leukemia (AML). Vor Biopharma, is a company that is testing a possible new treatment for AML. This possible new treatment, is VOR33. In this study, your blood-forming stem cells will be genetically modified to become VOR33. VOR33 has not been approved by the Food and Drug Administration (FDA). This is a first time VOR33 is being studied in humans. The sponsor of this study is looking to find out if VOR33 is safe.
This study is closed
Investigator
Markus Mapara, MD
Are you between the ages of 18-70? |
Yes |
No |
Have you been diagnosed with Acute Myeloid Leukemia (AML)? |
Yes |
No |